Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Fresenius Faces French Damages Over Alimta

Eli Lilly Claims Victory In Dispute On Pemetrexed Patent

Executive Summary

Fresenius Kabi must pay Eli Lilly €28m in damages after a French court of first instance found that the generics firm’s pemetrexed infringed intellectual property protecting the Alimta chemotherapy brand. The German firm has commented on possible next steps.

You may also be interested in...

Stada Faces Damages On German Pemetrexed Reversal

In its half-year report, Stada has confirmed it continues to face the threat of damages from Eli Lilly, following its ‘at-risk’ launch in Germany of an alternative to the originator’s Alimta in July 2018.

Germany invalidates patent on pemetrexed

Germany’s federal patent court, the Bundespatentgericht, has declared invalid the German section of European patent EP1,313,508 that protects Eli Lilly’s Alimta (pemetrexed) cytostatic drug until 2021. Stada’s Stadapharm subsidiary immediately capitalised on the ruling, which has not yet been published, to launch a generic rival in the German group’s domestic market.

UK Court Shakes Up Test For Equivalent Infringement In Lilly/Actavis Case

The UK Supreme Court has shaken up the test for equivalent infringement in the UK, which is good news for patent owners out to catch infringers.


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts